source
- Merck touts promising ADC sacituzumab tirumotecan as potential cornerstone therapy at ASCOMerck highlighted a new antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), licensed from Chinese biotech Kelun-Biotech, at the ASCO meeting. The company said early clinical data have give…
- Positive data from Bristol Myers in multiple myeloma and Pfizer in lung cancer unveiled at ASCOAt the American Society of Clinical Oncology (ASCO) meeting, Bristol Myers Squibb presented early-stage results that showed a favorable response in a multiple myeloma trial. The data suggest the in…